Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03782636
Other study ID # 13341
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date January 28, 2019
Est. completion date September 2022

Study information

Verified date October 2021
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.


Description:

Investigators know that the longer people with diabetes can produce their own insulin, the better it is for the control of their blood glucose levels and long-term complications. People get type 1 diabetes because their immune system, the part of the body, which helps fight infections, mistakenly attacks and destroys the beta cells in the pancreas that produce insulin. As the immune system destroys these insulin-producing cells, the body's own ability to produce insulin decreases and diabetes develops. At diagnosis, there are usually a small number of beta cells (10-20%) left in the pancreas, which still produce small amounts of insulin. This is called 'beta cell function' and it is assessed by measuring C-peptide, which is a protein made by the pancreas when insulin is produced. Most people with type 1 diabetes eventually stop producing insulin themselves, this may occur rapidly in a few months, or more slowly over several years. New treatments preserving insulin production could improve management of diabetes. This could be done by using drugs acting on cells of the immune system. In type 1 diabetes, there is an imbalance between cells of the immune system, and there is evidence that one protein produced by our body, called Interleukin-2, could help in resetting the balance between those cells. It is important to start this treatment soon after diagnosis because this when there is the best chance of saving the beta cells still left in the pancreas.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 41
Est. completion date September 2022
Est. primary completion date April 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria: 1. Have given written informed consent to participate or assent with parental consent 2. Be aged 6-18 years 3. Be diagnosed with T1D (Type 1 Diabetes) (at least one autoantibody positive), requiring insulin treatment 4. Be within 6 weeks from diagnosis of T1D (at screening) 5. Have a random C-peptide > 200 pmol/l 6. Normal full blood count Exclusion Criteria: 1. Non-type 1 diabetes (type 2 or monogenic diabetes) and secondary diabetes 2. Pre-existing autoimmune disease (excluding type 1 diabetes) 3. Hypersensitivity to aldesleukin or any of the excipients 4. History of severe cardiac disease (NYHA Class III or IV) 5. History of malignancy within the past 5 years (with the exception of adequately treated basal or squamous cell carcinoma or cervical carcinoma in situ) 6. Clinically significant abnormal laboratory values (out of range and associated with clinical symptoms or signs) in haematology, biochemistry, thyroid, liver and kidney function 7. Pre-existing severe major organ dysfunction or seizure disorders 8. Participation in another clinical trial (CTIMP) within 4 months prior to screening 9. Females who are pregnant, lactating or intend to get pregnant during the study 10. Females of childbearing potential who are unwilling or unable to comply with contraceptive advice and regular pregnancy testing throughout the trial 11. Sexually active males who are unwilling or unable to comply with contraceptive advice 12. Current use of immunosuppressive agents or steroids 13. Current treatment with hepatotoxic, nephrotoxic, myelotoxic, or cardiotoxic products 14. Active clinical infections - participants can be recruited after a minimum period of 48 h after last day of feeling unwell or last day of antibiotic/anti-viral treatment 15. Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the participant ineligible for inclusion because of a safety concern 16. Children with compliance problems (families where the local investigators consider that problems with compliance may be an issue)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aldesleukin
PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion
Other:
Placebo
sterile diluent used for the aldesleukin preparation and 5% glucose

Locations

Country Name City State
United Kingdom Bristol Royal Hospital for Children Bristol
United Kingdom Addenbrooke's Hospital Cambridge
United Kingdom The Great North Children's Hospital Newcastle Upon Tyne
United Kingdom Nottingham Children's Hospital Nottingham
United Kingdom Oxford Children's Hospital Oxford Oxfordshire

Sponsors (5)

Lead Sponsor Collaborator
University of Oxford Centre for Statistics in Medicine, Oxford, JDRF, Oxford Clinical Trials Research Unit (OCTRU), Wellcome

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in slopes of DBS (Dried Blood Spot) C-peptide over the 6 month-treatment period between the active and placebo groups. Weekly DBS C-peptide collected during the 6-month treatment period, and then monthly during the 6 months of follow-up
Secondary Change in Treg, Teff and NK56bright cell frequencies and phenotypes from baseline At baseline and then1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (reported reactions using CTCAE grading v5.0) Assessment of the most commonly reported reactions to low- or high-dose aldesleukin, namely influenza-like syndrome, skin reaction, diarrhoea, nausea using CTCAE grading v5.0 At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (temperature in celsius) Vital signs - temperature in celsius At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (weight, in kilograms) Vital signs - weight, in kilograms At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (blood pressure: systolic/diastolic) Vital signs - blood pressure: systolic/diastolic At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (heart rate: bpm) Vital signs - heart rate: bpm At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (AST, ALT, ALP, GGT units per liter (U/L) Abnormal laboratory parameters liver function (AST, ALT, ALP, GGT units per liter (U/L) At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit total bilirubin - milligrams per deciliter (mg/dL) Abnormal laboratory parameters liver function total bilirubin - milligrams per deciliter (mg/dL) At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (urea and creatinine - mmol/L) Abnormal laboratory parameters kidney function (urea and creatinine - mmol/L) At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Safety will be assessed at each visit (full blood count - 109/L) Abnormal laboratory parameters full blood count - 109/L At screening, baseline and then 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Changes in the absolute numbers of T, B and NK (Natural Killer) cells. At baseline and then, 1, 2 , 3, 6 and 12 months from the beginning of treatment
Secondary Change in HbA1c and daily insulin requirements during the trial period. HbA1c - At baseline and then 3,6 and 12 months Insulin dose data -Baseline and then 1, 2, 3, 6 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05536232 - Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet N/A
Completed NCT04255381 - Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID) N/A
Completed NCT04625595 - Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes Phase 1
Active, not recruiting NCT06177691 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study
Completed NCT04002557 - Optimising Consultation Summaries to Promote Good Health
Completed NCT05876273 - Neural-net Artificial Pancreas (NAP) N/A
Withdrawn NCT03236558 - The Role of the Thymus in Type I Diabetes. N/A
Completed NCT03179280 - Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia N/A
Completed NCT06253351 - Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age With Type 1 Diabetes
Completed NCT01357603 - Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM Phase 1
Completed NCT04233034 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes Phase 3
Not yet recruiting NCT06408207 - CGM Academy for Youth With Type 1 Diabetes N/A
Recruiting NCT06408558 - Safe Use of New Technologies in Diabetes in Flight N/A
Completed NCT04520971 - Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes N/A
Recruiting NCT05766657 - Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases N/A
Completed NCT01838083 - Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus Phase 1